+39 02 610346.1 - info@newron.com


Ralfinamide is a unique, well-tolerated New Chemical Entity that specifically targets voltage-gated sodium channels originating from Newron’s ion channel program and is developed for a rare neuropathic pain indication. It is believed to mediate its potent analgesic effect through the inhibition of sodium channels, including Nav 1.7, N-type Calcium channels and NMDA receptor. Newron is looking for partners to advance the program into potentially pivotal studies in orphan indications in neuropathic pain.